References
- Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332(20): 1330–5
- Rice L, Huffman DM, Levine ML, et al. Heparin-induced thrombocytopenia/thrombosis syndrome: clinical manifestation and insights. (Abstr) Blood 1986; 68(5 Suppl 1): 339a
- Warkentin TE, Keiton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101(5): 502–7
- Warkentin TE, Elavathil LJ, Hayward CP, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127(9): 804–12
- Srinivasan AF, Rice L, Thompson J, et al. Coumadin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. (Abstr) Blood 2001; 98: 271a
- Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99(1): 73–80
- Greinacher A. Treatment of heparin-induced thrombocytopenia. Thromb Haemost 1999; 82(2): 457–67
- Lewis BE, Wallis DE, Berkowiti SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103(14): 1838–43
- Mangani HN. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997; 8: 74–87
- Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998; 35(4 Suppl 5): 26–34
- Farner B, Eichler P, Kroll H, et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85(6): 950–7